Company ProfilePremium

Tycoon Group Holdings Limited

Company Profile Analysis

Ticker: 3390.HK滿貫集團控股有限公司

ESOMAR 23 Corporate BadgeISO Certifications Badge
Tycoon Group Holdings Limited - Company showcase

Year Founded & Workforce

2015

199 Employees

Tycoon Group Holdings Limited logo

Tycoon Group Holdings Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Tycoon Group Holdings Limited Overview

Tycoon Group is a Hong Kong-based, founder-controlled omnichannel brand marketing and distribution integrator for proprietary Chinese medicines (PCM), health supplements, skincare and personal care products. It sits between brand owners and retailers, providing brand agency, marketing, promotion, logistics and sell-in to chain retailers, pharmacies and traders, and supplements this with a Hong Kong PCM retail chain (Hong Ning Hong, 70%-owned) and a Mainland China cross-border e-commerce operation (Combo Win Asia group, reconsolidated in March 2025). The group reports coverage of nearly 100,000 online and offline points of sale across Hong Kong, Macau, Mainland China and Southeast Asia, representing over 300 brands and more than 2,000 SKUs, and owns more than 60 registered trademarks for self-owned brands such as Boost & Guard Pro and Craft by Wakan [S1]. It is a micro-cap (~HK$219M) with thin margins (FY2025 net margin 1.4%), elevated short-term leverage, a highly concentrated customer base and a strategic minority shareholder, Jacobson Pharma (17.04%) [S1].


Company's own description (FY2025 annual results, paraphrased)

The company describes itself as a Hong Kong-based omnichannel marketing and management service integrator of healthcare and wellbeing products, offering one-stop brand agency, promotion and marketing, management, distribution and sales services for PCM, health supplements, skincare, personal care and other healthcare products. It claims a network of nearly 100,000 online and offline sales points across Hong Kong, Macau, the PRC and Southeast Asia, more than 300 represented brands and a portfolio of over 2,000 products, and characterises itself as a diversified industry pioneer with a leading market position in Hong Kong [S1]. The company also states it is one of the major PCM distributors in Hong Kong and has established relationships with the top two personal care chain retailers in Hong Kong [S5][S6].

Business model and revenue model

Channel / segmentModelFY2025 external revenue (HKD Mn)Share
DistributionWholesale sell-in of agency, collaborative and own-brand products to chain retailers, non-chain retailers (mainly pharmacies) and traders in HK, Macau, Mainland China and Southeast Asia701.664.0%
E-commerceCross-border e-commerce wholesale and online flagship stores plus domestic offline distribution in Mainland China (Combo Win Asia group)243.422.2%
Retail storeBrick-and-mortar PCM / proprietary medicine retail through Hong Ning Hong Limited (70%)151.713.8%

All revenue is recognised as sale of goods at a point in time (FY2025: HK$1,096.6M, 100%) [S1]. There is no disclosed subscription, licensing or service-fee revenue line; the "omnichannel brand marketing and management services" are monetised through product margin rather than separately invoiced fees. The revenue model is therefore effectively 100% product resale, with three channels:

Source: [S1] segment note.

Value-chain position

Tycoon occupies the mid-stream "market expansion services" layer: it does not manufacture (product sourcing via procurement centres in Japan, South Korea, Singapore, Malaysia, Thailand, Vietnam, Indonesia, Cambodia, Macau, Australia and France) [S1], but owns brand IP for self-owned lines, holds exclusive territorial agency rights for third-party brands, and controls a small downstream retail footprint. Margin capture improves with own-brand mix; agency/distribution volumes depend on brand-owner contracts and retailer access.

Customer types and end-markets

Chain retailers: the largest single customer ("Customer A", distribution segment) contributed HK$457.6M in FY2025 (41.7% of group revenue) and HK$471.8M in FY2024 (53.9%) [S1][S3]. The company does not name it; given its stated relationships with Hong Kong's top two personal care chains, it is likely one of those chains (unconfirmed).

Non-chain retailers: (independent pharmacies) and traders.

Consumers: via HNH retail stores and Mainland online flagship stores.

End-markets: Hong Kong local consumers and Mainland Individual Visit Scheme (IVS) tourists; Macau; Mainland China cross-border e-commerce shoppers; Chinese-diaspora and local consumers in Singapore, Malaysia and Thailand [S1][S2].

Independent characterisation

Tycoon is best understood as a leveraged, working-capital-intensive consumer-health distributor whose reported growth has been dominated by consolidation accounting (the 2023 deconsolidation and 2025 reconsolidation of its Mainland e-commerce arm) rather than organic expansion. Its underlying Hong Kong distribution franchise has been flat (HK$533.0M in FY2024 to HK$524.2M in FY2025) [S1]; Southeast Asia has grown from a low base but was deliberately cut back in 1H2026 to improve margin [S2]. Gross margin (24–27%) sits well below brand-owning peers such as JBM Healthcare (55.8%) [S14], reflecting a distribution-heavy mix. The equity story rests on own-brand margin expansion, Southeast Asian penetration and synergies with Jacobson Pharma, against persistent risks from customer concentration, refinancing of short-dated bank debt and a controlling-shareholder pledge history.

Strategy

Stated strategic themes (FY2025 annual results and 1H2026 interim)

Management's outlook heading for both periods is "Empowering the Growth, Embracing the NEW" [S1][S2]. Paraphrased pillars:

  1. Southeast Asian regional coverage — consolidate share in Singapore, Malaysia and Thailand; deploy sales in Vietnam, Indonesia and Cambodia; target comprehensive SEA coverage [S1][S2].

  2. Margin over volume in SEA — 1H2026 pivot away from low-margin SKUs toward higher-margin products [S2].

  3. Own and collaborative brands — invest in higher-margin own brands across categories for SEA, local and Mainland travellers; >60 trademarks [S1].

  4. Shareholder synergies with Jacobson — use Jacobson's pharmaceutical regulatory network to accelerate market-entry qualifications in Vietnam, Indonesia and Cambodia [S1][S2].

  5. Cost discipline — "stringent" cost control, reduced administrative expenses and finance costs [S2].

  6. Mainland e-commerce optimisation — product-mix optimisation, more international-brand online flagship stores, market-driven bestsellers amid consumption downgrading [S2].

Initiatives announced in the last 24 months

InitiativeDateDetailSource
CWA reconsolidationFeb–Mar 2025Put-option repurchase of 51% CWA; e-commerce segment restored[S1]
Jacobson strategic subscriptionApr–May 202594M shares at HK$0.50; HK$46.7M net for inventory (26.0), logistics (12.0), marketing (5.0), working capital (3.7) — fully used by Dec 2025[S1]
Sido Muncul partnershipFY2025Exclusive Malaysian F&B-channel agency for Kuku Bima Ener-G![S1]
Po Chai Pills Singapore exclusivityFY2025Exclusive agency via major chain retail in Singapore; extended to Cambodia by 1H2026[S1][S2]
HNH Mong Kok storeFY2025New retail outlet in tourist hotspot[S1]
Po Wo Tong concept storeEnd-2025Harbour City pop-up; celebrity endorsement (Selena Lee)[S1]
New century-old collaborative brandFY2025Name not disclosed[S1]
Unichi exclusive agency (HK)1H2026Hair-growth gummies[S2]
SEA product-mix restructuring1H2026Deliberate reduction of low-margin lines[S2]
Auditor change for cost-effectivenessNov 2025PwC → Crowe[S8]
Disposal of a subsidiary1H2026Gain HK$4.3M; identity not disclosed[S2]

Medium-term targets / guidance

No quantitative medium-term financial targets are publicly disclosed. Qualitative guidance: 2H2026 revenue expected to improve on seasonal peak and cost control, with the group aiming to stay profitable [S2][S6]; Thailand higher-margin sales expected to grow healthily in 2026 [S2].

Products & Services

Pricing models for individual SKUs are not publicly disclosed; all products are sold on a wholesale-price (distribution) or retail-price (HNH, online flagship) basis. Launch years are given only where disclosed.

Self-owned brands (higher-margin; >60 registered trademarks) [S1][S2][S3]

BrandProductDescription / positioningStatus / notes
Boost & Guard Pro (BG Pro 博健專研)BG Pro Immunoglobulin CapsulesImmune-support supplementBest-seller FY2024–FY2025
BG ProBG Pro Ultra Purity Deep Sea Fish OilOmega-3 supplementBest-seller FY2024–1H2026
BG ProBG Pro Dr. Growth CalciumChildren's growth calciumBest-seller 1H2026
BG ProBG Pro CoQ-10 (medical-grade)Cardiovascular / energy supplementUpgraded/improved line
BG ProBG Pro Brain BoosterCognitive supplementLaunched FY2024
Craft by Wakan (和漢匠心)Craft by Wakan Japanese ProbioticsMulti-strain probiotic (Japan-sourced)Best-seller FY2024–1H2026; previously endorsed by Ms. Lin Min Chen
Craft by WakanJapan Liver Boost EXLiver-support supplementUpgraded line
Craft by WakanJapan Joint ActiveJoint-health supplementUpgraded line
Craft by WakanJapan SlimProSlimming formulaLaunched FY2024
Legacy predecessors"Boost & Guard (BG 博健科研)", "Wakan (和漢)", "Kinmen (金門)"Own brands named in FY2022Evolved into current lines [S4]

Collaborative brands [S1][S2]

BrandProductsNotes
Kinmen Qiangxiao (金門強效)I-Tiao-Gung Plaster (essential-oil patch); I-Tiao-Gung Pain Relief Penetrating Liquid; I-Tiao-Gung Pain Relief Roller CreamTopical pain relief; ambassador Mr. Louis Cheung; liquid and roller cream launched FY2024
SEASONS (田心日辰)SEASONS NMN 40000Anti-ageing NMN supplement; ambassador Ms. Christine Kuo
MiTimeMiTime Multivitamin; MiTime Kids DHA 60 Softgels (fish/algal oil)Family / children's nutrition
Po Wo Tong (寶和堂)Dampness Removing Pills; Dampness Removing Bath CapsuleCentury-old HK brand acquired personally by the chairman and co-developed with the group; ambassador Ms. Selena Lee; Harbour City pop-up concept store since end-2025
Unnamed century-old brand—A new century-old collaborative brand added during FY2025 [S1]

Agency / third-party brands (selected, as disclosed) [S1][S2][S3][S4]

Brand (owner)CategoryRights / territory
Li Chung Shing Tong Po Chai Pills 李眾勝堂保濟丸 (JBM Group)PCM (digestive)Represented in HK; exclusive agency in Singapore (major chain retail, from FY2025) and Cambodia (from 1H2026)
Ho Chai Kung 何濟公 (JBM Group)PCMRepresented
Flying Eagle Medicated Oil 飛鷹活絡油 (Europharm / JBM Group)Topical PCMRepresented; exclusive in Singapore for Europharm Singapore products
Tin Hee Tong 天喜堂 incl. Tin Hee Pills (JBM Group)PCMRepresented
Kuku Bima Ener-G! (Sido Muncul, Indonesia)Energy-drink powderExclusive agency, food & beverage channel, Malaysia (from FY2025)
UnichiBear-shaped hair-growth gummiesExclusive agency, Hong Kong (disclosed 1H2026)
Kaminowa (Japan)Hair-loss prevention/careExclusive agency HK, Macau, Singapore
Helaslim (Japan)Slimming / beautyExclusive agency, Singapore
PNKids (Singapore)Children's multivitaminsExclusive, Singapore and Malaysia (obtained FY2024)
plu (Korea)Body careDistribution rights HK, Macau, Singapore, Malaysia (FY2024)
Dong-E-E-Jiao 東阿阿膠 (Mainland)Donkey-hide gelatin tonicGeneral distributor in Hong Kong (from FY2024)
Taiji Huoxiang Zhengqi Oral Liquid 太極牌藿香正氣口服液PCM oral liquidRepresented in Hong Kong (FY2024)
TJ-TYT (Toong Yin Thong) — Watermelon Frost Complex Powder, Pil Tu Tong, Vegetarian Bai Feng WanPCMDistribution rights in Malaysia since 2022
Double Panda 雙熊貓牌 — Qian Li Zhui Feng You, De-Kof cough syrup, American Ginseng CapsulesPCM / tonicSingapore and Malaysia
Culturelle®ProbioticsSole distributor in China (FY2022); exclusive HK & Macau (FY2024) — current status not reconfirmed in FY2025 disclosures
Biolane (France)Baby wash careExclusive HK, Singapore, Malaysia (FY2022–FY2024) — not reconfirmed in FY2025
Dr Banggiwon (Korea)Anti-hair-lossExclusive HK (FY2022) — not reconfirmed later
Nu-Prep (Biotropics Malaysia)Herbal healthExclusive HK & Macau (FY2022) — not reconfirmed later

Services

Omnichannel brand marketing & management: brand agency, promotion (TV, outdoor, Xiaohongshu social campaigns, celebrity ambassadors), management, distribution and sales; monetised via product margin, no separate fee disclosure [S1].

Co-development with retailers: active collaboration with two major Hong Kong personal-care chains to launch tailored products [S1].

Retail (HNH): retail and wholesale of pharmaceutical products and proprietary medicines; stores include a new Mong Kok outlet (FY2025); exact store count not publicly disclosed (one outlet at the May 2023 acquisition) [S1][S3].

Financial Narrative

All figures audited, HK$M, fiscal years ended 31 December. Sources: [S4] (FY2021–FY2022), [S3] (FY2023–FY2024), [S1] (FY2025); cash flow and some ratios from S&P Global via StockAnalysis [S7]; derived figures marked.

Income statement

FY2023 includes non-recurring gains of HK$186.7M (CWA 51% disposal), HK$10.0M (Five Ocean JV disposal), HK$6.5M (JBM share fair-value gain) and HK$1.4M (remeasurement) [S3]. Company-reported adjusted net profit (non-HKFRS): FY2023 HK$114.8M; FY2024 HK$46.4M; discontinued from FY2025 [S3][S1].

Margins (derived)

Revenue CAGR FY2021–FY2025: 5.4% (derived: (1096.6/888.9)^(1/4) − 1). This headline masks two consolidation swings; the underlying Hong Kong distribution book grew only 3.3% in FY2024 and contracted 1.7% in FY2025 [S3][S1].

Commentary. FY2021 was loss-making on inventory write-downs (HK$10.5M) and COVID-era disruption. FY2022 delivered record revenue (HK$1,186.2M) and a 4.9-point gross-margin expansion driven by product-mix optimisation, Mainland "Double 11" e-commerce sales of ~HK$166M and lower write-downs [S4]. FY2023's HK$297.3M profit was overwhelmingly one-off (disposal gains ~HK$203M); underlying operating profit was ~HK$133.7M (derived: reported operating profit less other gains). FY2024 revenue fell 26.9% on CWA deconsolidation, and profit collapsed to HK$6.0M with share-based payments jumping to HK$20.6M [S3]. FY2025's 25.2% revenue rebound was "mainly due to" CWA reconsolidation per management, with gross margin down 2.0 points to 24.6% on unabsorbed procurement-cost increases [S1]. Net profit recovered to HK$15.5M helped by lower share-based payments (HK$6.5M) and a HK$4.4M remeasurement gain.

Interim trend (1H2026 vs 1H2025) [S2]

Two-thirds of the 1H2026 pre-tax profit (HK$4.3M of HK$9.3M) came from a one-off gain on disposal of an undisclosed subsidiary; the remainder reflects G&A savings (staff costs down from HK$43.3M to HK$31.4M) and lower interest [S2].

Balance sheet

Gearing ratio per company definition (net debt / (equity + net debt)) is disclosed only for FY2023–FY2025 in the documents reviewed; FY2021–FY2022 shown as 0 = not disclosed in sources reviewed (derived equivalent: FY2021 39.1%, FY2022 47.7%). FY2025 goodwill HK$203.8M and other intangibles HK$51.5M per S&P breakdown [S7]. At 30 Jun 2026: cash HK$22.3M, bank and other borrowings HK$303.1M, shareholder loans HK$99.9M, lease liabilities HK$7.3M, equity HK$550.0M, gearing 41.7% [S2].

Commentary. The balance sheet has become more levered and less liquid. Cash fell to HK$22.3M at mid-2026 against HK$294.5M of bank debt due within one year [S2]. Shareholder loans doubled in FY2025 (new HK$16.9M loan maturing May 2030; HK$85.0M maturing March 2028) [S1]. Intangibles tripled to HK$255.3M on CWA reconsolidation, creating impairment exposure if Mainland e-commerce underperforms. Prepayments to suppliers (HK$294.3M at FY2025, HK$310.2M at 1H2026) now exceed trade receivables in some periods; management disclosed that only ~26.4% of the 30 Jun 2026 prepayment balance had been utilised by the interim announcement date [S2] — a key quality-of-assets monitorable.

Cash flow [S7]

The company states it did not repurchase its listed securities in FY2024 or FY2025 [S3][S1]; the S&P "repurchase" line most likely reflects share purchases by the share award scheme trustee (consistent with weighted-average shares of 776.2M vs 800M issued in FY2024) — unconfirmed. TTM to 30 Jun 2026: OCF HK$33.8M, FCF HK$33.7M [S7].

Commentary. Free cash flow was negative in three of five years as working capital absorbed HK$470M cumulatively over FY2021–FY2024. FY2025 was the first strongly cash-generative year (FCF HK$96.5M), driven by receivable and inventory releases [S7]. Capex is negligible (asset-light model). Dividends paid in FY2023–FY2024 (HK$80M combined) were funded alongside rising bank borrowings, which roughly doubled during FY2024 [S3].

Ratios (derived unless stated)

FY2023 interest coverage on underlying operating profit (ex ~HK$203M gains) ≈ 5.7x; FY2023 net debt / underlying EBITDA (~HK$156M) ≈ 1.1x. FY2023 working-capital days are distorted by CWA deconsolidation at year-end. S&P's TTM view (to Jun 2026): ROE 5.49%, ROA 2.77%, ROIC 4.84%, current ratio 1.44, debt/equity 0.75, interest coverage 2.64 [S7].

Commentary. Returns on capital have been sub-cost-of-capital since FY2024. The cash conversion cycle lengthened sharply in FY2024 (132 days) as DSO jumped above 110 days and payables were paid down; FY2025 improved but remains above the FY2021–FY2023 range. Receivables aged over 180 days were HK$62.0M at FY2025 (20.8% of gross) and HK$47.1M at 1H2026 [S1][S2].

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Revenue by Segment

Segment (external revenue, HKD Mn)FY2023FY2024FY2025

Distribution

684.3699.6701.6

E-commerce

406.40243.4

Retail store

108.0176.4151.7

Total group revenue

1,198.6876.01,096.6

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Revenue by Segment by Segment Result

Segment result (HKD Mn)FY2023FY2024FY2025

Distribution

94.957.351.1

E-commerce

48.4-3.36.9

Retail store

7.69.01.2

Total segment results

150.962.959.2

Segment Margins & Growth (%) and Revenue by Segment (%)

Metric (%)FY2023FY2024FY2025

Distribution result margin

13.98.27.3

Retail store result margin

7.05.10.8

Distribution share of group revenue

57.179.964.0

E-commerce share of group revenue

33.90.022.2

Retail store share of group revenue

9.020.113.8

Revenue by Segment (FY2021–FY2022)

Segment (legacy basis, external revenue HKD Mn)FY2021FY2022

E-commerce

546.0738.7

Distribution

339.7447.5

Others (retail)

3.20

Revenue by Segment — E-commerce

Segment result (legacy basis, HKD Mn)FY2021FY2022

E-commerce

17.740.7

Distribution

-7.842.2

Others

-1.80

Segment Revenue

Segment1H2025 revenue1H2026 revenueYoY1H2025 result1H2026 result

Distribution

343.4306.0−10.9%17.87.3

E-commerce

87.4127.6+45.9%−3.713.4

Retail stores

79.262.5−21.2%1.0−2.6

Total

510.1496.1−2.7%15.118.1

Group Entities

EntityRoleOwnership

Tycoon Empire Investment Limited (BVI)

Immediate and ultimate holding company

Controlling shareholder

Dynasty Garden Limited

Holding vehicle for CWA

Indirect wholly-owned

Combo Win Asia Limited and subsidiaries

Mainland e-commerce / distribution

100% since 28 Feb 2025

Hong Ning Hong Limited (HNH)

HK PCM retail / wholesale

70% since Mar 2024

Million Effort Investment Limited

Holding vehicle (HNH stake, Five Ocean)

Wholly-owned

Key Zone Investment Inc.

Holding vehicle (Jefferine Macau)

Wholly-owned

Jefferine Macau Limited

Macau distribution

100% since Apr 2022

Fu Qing Chinese Medical Trading Pte. Ltd.

Singapore distribution

Acquired Aug 2021

Singapore and Malaysia subsidiaries

SEA distribution (established pre-listing)

Wholly-owned (per disclosure)

Income Statement and Per-Share Data

Metric (HKD Mn)FY2021FY2022FY2023FY2024FY2025

Revenue

888.91,186.21,198.6876.01,096.6

Cost of sales

737.2924.6877.5643.4826.6

Gross profit

151.7261.5321.1232.7270.0

Selling & distribution expenses

97.2121.4108.5109.9135.3

General & administrative expenses

65.272.984.595.395.5

Other gains/(losses), net

-0.3-5.6202.90.31.5

Operating profit (reported)

-7.864.9336.630.043.5

Finance costs

6.311.323.421.222.0

EBITDA (FY2023–FY2025 company-reported; FY2021–FY2022 derived)

5.479.7360.841.964.0

Profit before tax

-17.550.4317.75.517.5

Net profit (incl. NCI)

-17.443.6297.36.015.5

Net profit attributable to owners

-18.843.8297.33.215.7

EPS basic (HK cents)

-2.06.038.00.41.9

EPS diluted (HK cents)

-2.06.038.00.41.9

Dividend per share (HK cents)

03.07.000

Margin (%)

Margin (%)FY2021FY2022FY2023FY2024FY2025

Gross margin

17.122.026.826.624.6

Operating margin (reported)

-0.95.528.13.44.0

EBITDA margin

0.66.730.14.85.8

Net margin (incl. NCI)

-2.03.724.80.71.4

Margin Analysis (%) and Per-Share Data

Metric1H20251H2026Change

Revenue

510.1496.1−2.7%

Gross profit

129.2122.5−5.2%

Gross margin

25.3%24.7%

−0.6pt

S&D expenses

71.770.4−1.9%

G&A expenses

51.038.2−25.1%

Other gains, net

2.96.0

incl. HK$4.3M disposal gain

Finance costs

12.810.7−16.6%

Profit/(loss) before tax

−7.49.3

turnaround

Net profit/(loss)

−7.76.3

turnaround

Attributable to owners

−8.07.1

turnaround

EBITDA

15.930.9+94%

EPS basic (HK cents)

−11—

Balance Sheet and Margin Analysis (%)

Metric (HKD Mn)FY2021FY2022FY2023FY2024FY2025

Total assets

881.51,012.1989.01,005.61,170.3

Cash & equivalents

71.674.639.134.070.3

Inventories

303.2341.8141.3167.0173.9

Trade receivables

205.0256.2236.6270.6296.9

Prepayments, deposits & other receivables

108.3147.7161.3252.5294.3

Goodwill & intangibles

40.138.786.282.9255.3

Bank borrowings (all current)

179.0278.4139.0270.3310.4

Shareholder loans

50.050.050.050.0101.9

Lease liabilities

10.113.217.110.715.8

Total debt incl. leases

239.1341.6206.2331.0428.1

Short-term debt (current)

235.5338.6197.3326.5408.4

Long-term debt (non-current)

3.63.08.94.519.6

Net debt

167.5267.0167.1297.0357.7

Total equity

261.3293.2543.5489.0545.2

Equity attributable to owners

257.9293.6536.2478.9537.0

Working capital

77.5114.9233.4264.1238.5

Gearing ratio, company definition (%)

0023.838.340.0

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Cash Flow

Metric (HKD Mn)FY2021FY2022FY2023FY2024FY2025

Operating cash flow

-36.2-52.211.9-76.697.0

Capital expenditure

7.91.53.92.30.5

Free cash flow

-44.1-53.68.0-78.996.5

Dividends paid

16.0052.028.00

Share purchases (per S&P "repurchases")

009.447.611.6

Change in working capital

-46.4-149.6-141.8-132.427.2

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2021FY2022FY2023FY2024FY2025

ROE % (attrib. profit / closing owners' equity)

-7.314.955.40.72.9

ROA % (net profit / closing total assets)

-2.04.330.10.61.3

ROIC % (op. profit × (1−16.5%) / (equity + net debt); FY2023 ex-gains)

-1.59.715.73.24.0

Current ratio (x)

1.131.161.541.521.40

Debt / equity (x, total debt incl. leases)

0.921.170.380.680.79

Net debt / EBITDA (x)

31.03.40.57.15.6

Interest coverage (x, op. profit / finance costs)

-1.25.714.41.42.0

Asset turnover (x, revenue / closing assets)

1.011.171.210.870.94

Days sales outstanding

84.278.872.1112.898.8

Days inventory outstanding

150.1134.958.894.776.8

Days payables outstanding

151.8119.565.275.164.9

Cash conversion cycle (days)

82.594.265.7132.4110.7

Revenue by Region

Region (revenue HKD Mn)FY2021FY2022FY2023FY2024FY2025

Hong Kong

225.2321.6623.7709.4680.3

Mainland China

558.8750.9413.90243.4

Macau

95.894.6112.789.388.0

Southeast Asia & others

9.119.248.477.385.0

Total

888.91,186.21,198.6876.01,096.6

Revenue by Region (FY2023–FY2025)

Country (revenue HKD Mn)FY2023FY2024FY2025

Singapore

41.865.669.6

Malaysia

5.59.615.0

Others (incl. Thailand)

1.12.10.4

Revenue by Region (%)

Region (YoY growth %)FY2022FY2023FY2024FY2025

Hong Kong

42.894.013.7-4.1

Macau

-1.219.1-20.7-1.5

Singapore

111.6121.256.96.1

Malaysia

0074.457.3

Geography Overview

GeographyDistributionE-commerceRetail storeTotal

Hong Kong

524.2 (+~4.4 reconciling)

—151.7680.3

Mainland China

—243.4—243.4

Macau

88.0——88.0

Singapore / Malaysia / others

85.0——85.0

Total

701.6243.4151.71,096.6

Geographic Revenue

Region1H20251H2026YoY

Hong Kong

336.6301.2−10.5%

Mainland China

87.4127.6+45.9%

Macau

42.943.7+1.8%

Southeast Asia

43.223.6−45.4%

— Singapore

36.617.8−51.4%

— Malaysia

6.35.7−9.4%

Share Price & Returns

Reference pointPrice (HKD)

IPO price (Apr 2020)

1.48 (bottom of range; one aggregator shows 1.49 — discrepancy noted)

Pre-collapse (mid-Apr 2025, implied by ~HK$2.53bn market cap / 800M shares)

~3.16

29 Apr 2025 close

0.400

31 Jul 2026

0.231

2 Oct 2026

0.249

16 Oct 2026

0.245

Valuation Multiples

MultipleTycoonBasis

P/E (TTM, attributable profit HK$30.8M)

7.1x

[S1][S2]

EV/EBITDA (TTM company EBITDA HK$79.0M)

7.7x

Derived

EV/Sales (TTM revenue HK$1,082.6M)

0.56x

Derived

P/B (equity attrib. HK$542.6M)

0.40x

[S2]

P/TBV

~0.77x

[S7]

FCF yield (TTM)

~15%

[S7]

Dividend metric

Dividend metricFY2021FY2022FY2023FY2024FY2025

Interim DPS (HK cents)

003.500

Final DPS (HK cents)

03.03.500

Total DPS (HK cents)

03.07.000

Dividends declared (HKD Mn)

024.056.000

Debt Maturity Profile

Maturity bucket (HKD Mn)FY2023FY2024FY2025

Within one year

131.1262.9301.1

Second year

0.50.51.4

Third to fifth years

1.51.63.1

Beyond five years

6.05.44.8

Analyst Conclusions

Management guidance

Qualitative only: 2H2026 revenue expected to improve given seasonal peak demand and cost control, with continued profitability; SEA to grow "healthier" on higher-margin mix; Thailand expected to grow; continued expansion into Vietnam, Indonesia and Cambodia with Jacobson's support [S2][S6]. No numeric targets.

Consensus

Not available (no coverage).

Bull case

  1. Valuation asymmetry: at ~0.40x book and ~7x trailing earnings with ~15% FCF yield, modest margin recovery could re-rate the equity [S7].

  2. Operating leverage from cost cuts: 1H2026 G&A fell 25.1% and finance costs 16.6%; if gross profit stabilises, recurring profit could exceed FY2025 levels [S2].

  3. Strategic optionality: Jacobson (17.04%) and JBM linkages create potential for deeper integration or corporate action, while SEA licences provide a platform few HK peers possess [S1].

Bear case

  1. Earnings quality: one-off gains drove much of recent profit (HK$4.3M of HK$9.3M 1H2026 PBT); underlying distribution results halved YoY (HK$17.8M to HK$7.3M) [S2].

  2. Liquidity squeeze: cash of HK$22.3M against ~HK$295M of bank debt due within a year, floating rates and 2.0x interest cover leave little buffer [S2].

  3. Concentration and asset risk: 41.7% customer dependence, HK$310M of supplier prepayments with slow utilisation and HK$204M of goodwill tied to an e-commerce unit that missed targets [S1][S2][S7].

Catalysts and monitorables (next 12 months)

  • FY2026 results (expected by end-March 2027) — 2H2026 revenue rebound and gross-margin trajectory.

  • Bank facility renewals and any new shareholder financing.

  • Utilisation of supplier prepayments and receivable ageing.

  • SEA revenue re-acceleration post-pruning; first Vietnam/Indonesia revenue.

  • Goodwill impairment testing on CWA under the new auditor (Crowe).

  • Further board changes (two NED departures in 14 months) and any change in controlling-shareholder stake or pledges.

  • Customer A relationship and any new exclusive agency wins or losses.

  • Dividend resumption (none since FY2023).

Analyst verdict

Tycoon Group is a sub-scale, founder-controlled consumer-health distributor that has spent three years navigating self-inflicted structural volatility: the 2023 sale of its Mainland e-commerce arm for a large accounting gain, the buyer's failure to pay HK$60M of consideration, and the 2025 forced repurchase that brought the business — and roughly HK$170M of goodwill and intangibles — back onto the balance sheet. Stripped of consolidation effects, the core Hong Kong distribution franchise is flat-to-declining, segment margins have halved since FY2023, and the much-promoted Southeast Asian expansion contracted 45% in 1H2026 as management prioritised margin over scale.

The investment case therefore hinges less on growth than on balance-sheet survival and earnings quality. Positively, FY2025 produced the group's strongest free cash flow in five years (HK$96.5M), management has cut G&A aggressively, and a credible strategic shareholder — Jacobson Pharma — injected equity at a premium after the April 2025 share-price collapse. The shares trade at roughly 0.4x book and 7x trailing earnings, pricing in considerable distress.

Negatively, liquidity is tight (HK$22M cash vs ~HK$295M of bank debt due within a year), asset quality warrants scrutiny (supplier prepayments of HK$310M, slow utilisation, aged receivables), customer concentration is extreme, and governance signals — a combined chair/CEO, a margin-call forced sale, an auditor resignation over fees and a revolving NED seat — argue for a meaningful discount. Profitability remains marginal and partly gain-dependent.

On balance, Tycoon is a high-risk, special-situation micro-cap rather than a quality compounder. Upside requires sustained recurring profit above HK$20M, successful refinancing and evidence that the SEA reset lifts margins. Until FY2026 audited results confirm improved cash conversion and stable bank funding, the.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleTenure / appointmentOther disclosed roles / background

Mr. Wong Ka Chun Michael (王嘉俊)

Chairman, Executive Director & CEO

Founder; responsible for strategy since inception

Personally acquired Po Wo Tong brand; controls Tycoon Empire Investment Ltd [S1]

Mr. Cao Ran (曹冉)

Non-executive Director

Since 1 Jul 2025

NED of Immunotech Biopharm (6978.HK) since Oct 2025 [S1][S9]

Ms. Liang Yan (梁艷)

Non-executive Director

On board by Mar 2025 (exact date not confirmed)

—

Ms. Li Ka Wa Helen (李家華)

Non-executive Director

On board since at least FY2022

—

Mr. Lau Ka On David (劉家安)

Non-executive Director

On board since at least FY2022

—

Mr. Chung Siu Wah (鍾兆華)

Independent NED

Since at least FY2022

—

Ms. Chan Ka Lai Vanessa (陳嘉麗)

Independent NED

Since at least FY2022

INED of China Renaissance (1911.HK) from Jun 2025; independent director of Hunan Junxin Environmental Protection (301109.SZ) from Aug 2025 [S1]

Mr. Mak Chung Hong (Mak Tommy Chung Hong) (麥仲康)

Independent NED

Since at least FY2022

—

“—” = not publicly disclosed.

Board & Management Changes

DateChange

10 Jan 2025

Mr. Cao Weiyong resigns as NED; Mr. Hu Yang appointed

By Mar 2025

Ms. Chong Yah Lien (NED in FY2022–FY2023) no longer on board; Ms. Liang Yan appears as NED

1 Jul 2025

Mr. Hu Yang resigns (work adjustment); Mr. Ng Kwan Ho (ex-JBM Healthcare, Amway HK marketing) and Mr. Cao Ran appointed NEDs

14 Aug 2026

Mr. Ng Kwan Ho resigns as NED

Major Shareholders

HolderStakeBasis / source

Tycoon Empire Investment Ltd (Mr. Wong Ka Chun Michael)

~35.7% (~319M shares)

Derived: 448.1M shares (56.01%, Oct 2023) [S3] less ~129M force-sold Apr 2025 [S10]; consistent with S&P insider ownership of 35.77% [S7]

Jacobson Pharma Corporation Ltd group (2633.HK)

17.04%

Company disclosure, Mar 2026 [S1]

Free float

~270M shares (~30%)

S&P estimate [S7]

Institutional ownership

Not publicly disclosed (S&P shows n/a)

[S7]

Competitive Landscape

Key Competitors

CompetitorSegment overlapDescription / positioningLatest scale (where retrieved)

JBM (Healthcare) Ltd (2161.HK)

PCM brands / distribution (also a partner)

Branded healthcare marketer; owns Po Chai Pills, Ho Chai Kung, Tin Hee Tong; acquired ~40 Chinese medicine clinics

FY Mar-2026 revenue HK$834.6M (+6.7%), GP HK$465.5M (55.8%), attributable profit HK$201.1M [S14]

Jacobson Pharma (2633.HK)

Generics / OTC (also shareholder)

Vertically integrated HK generics maker

FY Mar-2026 revenue HK$1,569.5M (−0.5%), GM 43.2%, attributable profit HK$301.6M [S15]

DKSH Holding (SIX: DKSH)

Market-expansion services, consumer health distribution in HK/SEA

Global outsourced distribution leader

FY2025 net sales CHF 11.1bn (+2.9% CER); Healthcare CHF 5.8bn [S16]

Zuellig Pharma

Healthcare distribution (HK/SEA)

Private regional distributor

—

China Resources Pharmaceutical (3320.HK)

Mainland pharma retail/distribution (pre-IPO investor)

State-backed distributor

—

Wai Yuen Tong Medicine (0897.HK)

HK PCM brands and retail

PCM manufacturer-retailer

—

Eu Yan Sang

PCM retail HK/SEA

Private (delisted)

—

Health & Happiness (1112.HK)

Supplements (Swisse) in HK/Mainland cross-border

Global VMS brand owner

—

By-health (300146.SZ)

Supplements, Mainland e-commerce

Leading Mainland VMS brand

—

Watsons / Mannings own-label

Retail-led supplements/personal care

Customers and competitors via private label

—

“—” = not publicly disclosed.

Peer Comparison FY2025

MetricTycoon (FY2025)JBM Healthcare (FY Mar-26)Jacobson Pharma (FY Mar-26)DKSH (FY2025)

Revenue

HK$1,096.6M

HK$834.6M

HK$1,569.5M

CHF 11.1bn

Revenue growth

+25.2% (reported; consolidation-driven)

+6.7%−0.5%

+2.9% (CER)

Gross margin

24.6%55.8%43.2%—

Net margin (attrib.)

1.4%

24.1% (derived)

19.2%—

Dividend

Nil

HK17.10 cents total

HK9.00 cents total

—

Recent Developments

The register extends slightly beyond 18 months to capture the CWA reconsolidation that shapes current reporting.

Company Snapshot

$140.8M

Revenue

199

Employees

$28M

Market Cap

2015

Founded

New Territories, Hong Kong

Headquarters

SWOT Analysis

Strengths

  • Entrenched chain-retail access: one customer bought HK$457.6M (41.7% of revenue) in FY2025 — evidence of deep shelf access [S1].
  • Heritage PCM brand portfolio via JBM (Po Chai Pills, Ho Chai Kung, Flying Eagle, Tin Hee Tong) with exclusive Singapore/Cambodia rights [S2].
  • Own-brand IP: >60 registered trademarks; bestsellers such as Craft by Wakan Probiotics and BG Pro Fish Oil [S1].
  • Strategic anchor shareholder: Jacobson subscribed at a 25% premium in May 2025 and holds 17.04% [S1].
  • Asset-light model: FY2025 capex only HK$0.5M; FCF HK$96.5M [S7].
  • SEA platform: SEA revenue grew from HK$19.2M (FY2022) to HK$85.0M (FY2025); licences in Thailand and Cambodia [S4][S1].

Weaknesses

  • Thin profitability: FY2025 net margin 1.4%; ROE 2.9% (derived) [S1].
  • Margin compression: distribution segment margin fell from 13.9% (FY2023) to 7.3% (FY2025) [S3][S1].
  • Short-dated leverage: HK$294.5M of HK$303.1M bank debt due within one year; cash HK$22.3M at Jun 2026 [S2].
  • Working-capital intensity: cash conversion cycle 110.7 days (FY2025); FCF negative in three of five years [S7].
  • Asset quality questions: prepayments HK$310.2M at Jun 2026 with only ~26.4% subsequently utilised; receivables >180 days HK$47.1M [S2].
  • Governance: combined chair/CEO (C.2.1 deviation); auditor resignation over fees; related-party trade payables HK$108.6M [S2][S8].

Opportunities

  • SEA expansion into Vietnam, Indonesia and Cambodia leveraging Jacobson's regulatory network [S2].
  • Higher-margin SEA mix after the 1H2026 pruning (Singapore/Malaysia margins improved) [S2].
  • Tourism recovery in HK (visitor arrivals +31% in 2024) supporting PCM souvenir demand [S3].
  • HK–ASEAN FTA upgrade widening tariff-preferred categories to ~600 [S3].
  • Collaborative heritage brands (Po Wo Tong, new century-old brand) with celebrity-led marketing [S1].
  • Mainland e-commerce recovery: e-commerce segment result swung to HK$13.4M profit in 1H2026 [S2].

Threats

  • Customer concentration: loss or renegotiation with Customer A would impair ~40% of revenue [S1].
  • Partner vertical integration: JBM expanding downstream (40 clinics) could reduce reliance on third-party distributors [S14].
  • Refinancing / interest-rate risk: all borrowings floating-rate; interest coverage 2.0x (FY2025, derived) [S1].
  • Goodwill impairment: goodwill HK$203.8M largely tied to CWA, which missed its performance targets in 2024 [S1][S7].
  • Consumer weakness: HK revenue −10.5% in 1H2026 on weak purchasing sentiment and strong HKD [S2].
  • Controlling-shareholder pledge risk: April 2025 forced sale demonstrated vulnerability to margin calls [S10].

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
10 Jan 2025NED Cao Weiyong resigns; Hu Yang appointed [S3]Board change
27 Jan 2025ECF serves put-option exercise notice on CWA 51% [S1]Reverses 2023 disposal
5 Feb 2025Announcement of put-option exercise [S1]Disclosure
28 Feb 2025CWA repurchase completed; net HK$46.0M paid [S1]E-commerce returns to group from 1 Mar 2025
19 Mar 2025Financial update flags sharp FY2024 profit decline [S3]Earnings warning
28 Mar 2025FY2024 results: revenue −26.9%, net profit HK$6.0M, no final dividend [S3]Earnings reset
16 Apr 2025Share price falls ~90% intraday; trading halt from 11:30 [S10]Market dislocation; pre-event market cap ~HK$2.53bn
~17 Apr 2025Resumption; disclosure that ~129M of chairman's shares were force-sold by brokers; stock rebounds ~77% [S10]Controlling stake falls from ~56% to ~36%
29 Apr 2025Subscription agreement with Jacobson Group Treasury (94M shares at HK$0.50, 25% premium) [S1]Strategic support after crash
16 May 2025Jacobson supplemental announcement explaining subscription rationale [S11]Investor confirmation
20 May 2025Use-of-proceeds announcement [S1]Allocation disclosed
22 May 2025Subscription completed; HK$46.7M net [S1]Liquidity
30 May 2025AGM adopts new articles of association [S1]Governance housekeeping
Jun 2025INED Chan Ka Lai Vanessa joins China Renaissance board [S1]Director change of info
1 Jul 2025Hu Yang resigns; Ng Kwan Ho and Cao Ran appointed NEDs [S9]Board refresh
8 Aug 2025Profit warning for 1H2025 (loss; higher share-based payments; CWA challenges) [S19]Earnings warning
29 Aug 20251H2025 results: net loss HK$7.7M; no interim dividend [S2]Weak 1H
Oct 2025NED Cao Ran joins Immunotech Biopharm board [S1]Director info
21 Nov 2025PwC resigns after failing to agree FY2025 audit fee; Crowe (HK) CPA appointed [S8][S1]Auditor change (one media report wrongly cited Grant Thornton; filings confirm Crowe)
FY2025HNH opens Mong Kok store [S1]Retail expansion
FY2025Exclusive agency wins: Kuku Bima Ener-G! (Malaysia), Po Chai Pills (Singapore chains) [S1]SEA portfolio
End-2025Po Wo Tong Wellness Concept Store opens at Harbour City [S1]Brand building
5 Mar 2026Positive profit alert: FY2025 PBT up ≥200%, revenue up ≥20% [S18]Earnings recovery
31 Mar 2026FY2025 results: revenue HK$1,096.6M (+25.2%), net profit HK$15.5M, no dividend [S1]Turnaround
16 Apr 2026Annual Report 2025 published [S1]Filing
29 May 2026AGM (scheduled) [S1]Governance
1H2026Unichi exclusive HK agency; Po Chai Pills exclusive in Cambodia; subsidiary disposal (gain HK$4.3M) [S2]Portfolio and portfolio pruning
14 Aug 2026Positive profit alert for 1H2026; NED Ng Kwan Ho resigns [S17][S2]Earnings / board
28 Aug 20261H2026 results: revenue −2.7%, net profit HK$6.3M; SEA sales −45.4% [S2]Profit sustained, top line soft
29 Aug 2026Results press release reiterates 2H2026 improvement expectation [S6]Guidance
Late Nov 2026 (est.)Next earnings-related date estimated by data vendor [S7]Monitorable

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

9 charts
Income Statement: Revenue & Gross Profit: Revenue rose from HKD 888.9 Mn in FY2021 to HKD 1,096.6 Mn in FY2025.
Tycoon Group Holdings Limited — Income Statement: Revenue & Gross Profit
Series (HKD Mn)FY2021FY2022FY2023FY2024FY2025
Revenue888.91,186.21,198.68761,096.6
Cost of sales737.2924.6877.5643.4826.6
Gross profit151.7261.5321.1232.7270

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. S1Tycoon — Annual Results Announcement FY2025 (and Annual Report 2025) — 31 Mar 2026 / 16 Apr 2026 · hkexnews.hk
  2. S2Tycoon — Interim Results Announcement 1H2026 — 28 Aug 2026 (www1.hkexnews.hk)
  3. S3Tycoon — Annual Results Announcement FY2024 — 28 Mar 2025 (www1.hkexnews.hk)
  4. S4Tycoon — Annual Results Announcement FY2022 — 29 Mar 2023 (www1.hkexnews.hk)
  5. S5FY2025 results press release (PR Newswire, via Kosmo) — 31 Mar 2026 (kosmo.com.my)
  6. S61H2026 results press release (PR Newswire, via Taiwan News) — 29 Aug 2026 (taiwannews.com.tw)
  7. S7S&P Global Market Intelligence data via StockAnalysis (income, balance sheet, cash flow, statistics) — Accessed Oct 2026 (stockanalysis.com)
  8. S8Change of auditor coverage (Tiger Brokers; FilingReader) — 21 Nov 2025 · filingreader.com
  9. S9Board changes (TipRanks) — Jul 2025 (tipranks.com)
  10. S10April 2025 share-price collapse / forced sale (Tiger Brokers; Moomoo; TipRanks) — Apr 2025 · moomooapp.com · tipranks.com
  11. S11Jacobson Pharma supplemental announcement on Tycoon subscription — 16 May 2025 (hkexnews.hk)
  12. S12IPO documents / SCMP coverage — 30 Mar 2020 · Scmp.com
  13. S13FY2023 results press release (Malay Mail / Media OutReach) — 28 Mar 2024 (malaymail.com)
  14. S14JBM Healthcare FY2026 results — 22 Jun 2026 · filingreader.com
  15. S15Jacobson Pharma FY2026 results — 23 Jun 2026 (www1.hkexnews.hk)
  16. S16DKSH FY2025 results — Feb 2026 (dksh.com)
  17. S17Tycoon positive profit alert 1H2026 — 14 Aug 2026 (www1.hkexnews.hk)
  18. S18Tycoon positive profit alert FY2025 — 5 Mar 2026 (www1.hkexnews.hk)
  19. S19Tycoon profit warning 1H2025 — 8 Aug 2025 (www1.hkexnews.hk)
  20. S20Tycoon Annual Report 2023 — 12 Apr 2024 (www1.hkexnews.hk)
  21. S21Moomoo company profile (Ipsos 2018 ranking, listing data) — Accessed Oct 2026 (moomooapp.com)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.